NewLimit has raised a $130M Series B led by Kleiner Perkins alongside NFDG, @khoslaventures.bsky.social, Human Capital and returning investors Dimension & Founders Fund

We're grateful for their boldness in joining us on our journey to extend human healthspan

blog.newlimit.com/p/newlimit-r...

each year @newlimitbio.bsky.social, we share an update on our progress with the public

this week, we revealed the early results from our programs in metabolism & immunology. we’re starting to see the first hints of reprogramming medicines on the horizon.

watch here: m.youtube.com/watch?v=HR0-...

2024 @newlimitbio.bsky.social:

- 10X Engine throughput
- Discovered TF sets that reprogram cell age & preserve type
- Restored youthful function in a disease model with drug-like reprogramming

we demonstrated that reprogramming medicines are possible

2025: we start to develop them

bit.ly/4h7rrD3

early autumn @newlimitbio.bsky.social:

- 0 → 70 TF sets tested in human hepatocytes via a chimeric liver system
- +2779 TF sets tested in T cells
- +51 sets that reverse phenotypic age in T cells
- 5 → 7 functional assays for hepatocyte age
- 0 → 80% efficiency LNP-mRNA delivery

bit.ly/4g0NKJV

late summer @newlimit

- world's largest partial reprogramming screen (again)
- 3x'd speed of sequencing turn-around
- 5x'd reprog factor library size
- built our first integrated reprog corpus for model training
- team += 3

blog.newlimit.com/p/july-augus...